On Monday, Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the Phase 3 VERIFY study of rusfertide for polycythemia vera.

For patients with a rare type of blood cancer, treatment might finally be coming out of the Dark Ages. People with the chronic condition polycythemia vera make too many red blood cells, thickening ...

Polycythemia vera is not hereditary. While it results from a genetic mutation, or a change in the DNA in a bone marrow cell, the change usually develops during life. It isn’t something you are born ...

Rusfertide, a hepcidin-mimetic peptide, reduces excess red blood cell production in polycythemia vera, addressing complications like blood clots and fatigue. The FDA granted rusfertide breakthrough ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Dear Dr. Roach: My husband (age 71) received a diagnosis of polycythemia vera a few years ago. I understand this variety of polycythemia isn’t caused by smoking, but we know that smoking does make it ...

Please provide your email address to receive an email when new articles are posted on . Rusfertide reduced need for phlebotomies and offered better hematocrit control than placebo. Results showed ...

The blood you don’t need could be exactly what someone else is praying for. It sounds inconceivable, yet for patients requiring frequent therapeutic phlebotomy—blood removal as treatment—this blood is ...

DEAR DR. ROACH: My husband (age 71) received a diagnosis of polycythemia vera a few years ago. I understand this variety of polycythemia isn’t caused by smoking, but we know that smoking does make it ...